EMPAPRO 10

About

EMPAPRO (empagliflozin) is an oral medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, designed for the management of type 2 diabetes mellitus. Its primary mechanism of action involves targeting the kidneys, where it selectively blocks the SGLT2 protein. This inhibition prevents the reabsorption of glucose from the filtered fluid back into the bloodstream, leading to increased excretion of glucose in the urine and a subsequent reduction in blood glucose levels.

Empagliflozin's glucose-lowering effect is independent of insulin secretion and sensitivity, making it a valuable therapeutic option. Beyond its efficacy in glycemic control, empagliflozin has demonstrated significant cardiovascular benefits, including a proven reduction in the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or heart failure, offering comprehensive patient care.

Uses

• To improve glycemic control in adults with type 2 diabetes mellitus.
• To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
• To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
• As an adjunct to diet and exercise.

Directions For Use

Take one tablet orally once daily in the morning, with or without food, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Effective reduction in blood glucose and HbA1c.
• Significant cardiovascular benefits, including reduced risk of death.
• Proven to reduce hospitalization for heart failure.
• Potential for modest weight loss.
• Low risk of hypoglycemia when used alone.
• Blood pressure reduction.

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination (polyuria)
• Thirst and dry mouth
• Nausea
• Dizziness or lightheadedness
• Hypotension (low blood pressure)
• Dehydration
• Ketoacidosis (rare, but serious)
• Acute kidney injury
• Fournier's gangrene (very rare, but serious)
• Increased cholesterol levels

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake can increase the risk of dehydration and affect blood sugar levels.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential renal effects on the fetus. Consult a doctor.
• Breastfeeding - Avoid during breastfeeding as it is unknown if empagliflozin is excreted in human milk. Seek medical advice.
• Liver - No dose adjustment is required for patients with hepatic impairment.
• Kidney - Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²). Dosage adjustment may be needed for moderate impairment.
• Lung - No specific contraindications related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.